The following anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed by the WHO International Working Group for Drug Statistics Methodology in April 2005. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology at whocc@nmd.no before 1 September 2005. If no objections are received before this date, the new ATC codes and DDDs will be considered final and be included in the January 2006 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy. The WHO Collaborating Centre for Drug Statistics Methodology can be contacted through e-mail: whocc@nmd.no. |
ATC level |
INN/Common name |
ATC code |
New ATC level codes (other than 5th level): |
|
|
| |
HMG CoA reductase inhibitors in combinations with other lipid modifying agents |
C10BA |
| |
HMG CoA reductase inhibitors, other combinations |
C10BX |
| |
Lipid modifying agents, combinations |
C10B |
| |
|
|
New ATC 5th level codes: |
|
|
| |
agomelatine |
N06AX22 |
| |
benfotiamine |
A11DA03 |
| |
bivalirudin |
B01AE06 |
| |
cilansetron |
A03AE03 |
| |
clofarabine |
L01BB06 |
| |
combinations |
R07AA30 |
| |
dexmedetomidine |
N05CM18 |
| |
efaproxiral |
L01XD06 |
| |
enalapril and calcium channel blockers |
C09BB02 |
| |
entecavir |
J05AF10 |
| |
fumagillin |
P01AX10 |
| |
galsulfase |
A16AB08 |
| |
loteprednol |
S01BA14 |
| |
olopatadine |
R01AC08 |
| |
palifermin |
V03AF08 |
| |
paricalcitol |
A11CC07 |
| |
pegaptanib |
S01XA17 |
| |
posaconazole |
J02AC04 |
| |
ranolazine |
C01EB18 |
| |
rotigotine |
N04BC09 |
| |
rufinamide |
N03AF03 |
| |
simvastatin and ezetimibe |
C10BA02 |
| |
tipranavir |
J05AE09 |
| |
zofenopril and diuretics |
C09BA15 |
ATC code changes:
INN/common name |
Previous ATC |
New ATC |
anagrelide |
B01AC14 |
L01XX35 |
atorvastatin and amlodipine |
C10AA55 |
C10BX031) |
lovastatin and nicotinic acid |
C10AA52 |
C10BA011) |
pravastatin and acetylsalicylic acid |
C10AA53 |
C10BX021) |
simvastatin and acetylsalicylic acid |
C10AA51 |
C10BX011) |
loteprednol |
S01BA14 |
|
ATC name changes
Previous |
New |
ATC code |
Agents used in photodynamic therapy |
Sensitizers used in photodynamic/ radiation therapy |
L01XD |
Cholesterol and triglyceride reducers |
Lipid modifying agents, plain |
C10A |
Other cholesterol and triglyceride reducers |
Other lipid modifying agents |
C10AX |
Serum lipid reducing agents |
Lipid modifying agents |
C10 |
New DDDs:
INN/common name |
DDD |
Unit |
Adm.R |
ATC code |
acemetacin |
0.12 |
g |
O |
M01AB11 |
acetyldihydrocodeine |
30.0 |
mg |
O |
R05DA12 |
ambroxol |
0.12 |
g |
O |
R05CB06 |
artemether |
120.0 |
mg |
P |
P01BE02 |
bivalirudin |
0.25 |
g |
P |
B01AE06 |
ciclesonide |
0.16 |
mg |
Inhal. aerosol |
R03BA08 |
cinacalcet |
90.0 |
mg |
O |
H05BX01 |
citalopram |
20.0 |
mg |
P |
N06AB04 |
darifenacin |
7.5 |
mg |
O |
G04BD10 |
dexketoprofen |
75.0 |
mg |
P |
M01AE17 |
duloxetine |
60.0 |
mg |
O |
N06AX21 |
efalizumab |
10.0 |
mg |
P |
L04AA21 |
eplerenone |
50.0 |
mg |
O |
C03DA04 |
ibandronic acid |
2.5 |
mg |
O |
M05BA06 |
lanthanum carbonate |
2.25 |
g2) |
O |
V03AE03 |
sevelamer |
6.4 |
g |
O |
V03AE02 |
strontium ranelate |
2.0 |
g |
O |
M05BX03 |
treprostinil |
4.3 |
mg |
P |
B01AC21 |
zolmitriptan |
2.5 |
mg |
N |
N02CC03 |
2) expresses as lanthanum
Change of DDDs
(Note that the changes will not be implemented before January 2006).
INN/common name |
Previous DDD |
New DDD |
ATC Code |
amprenavir |
2.4 g O |
1.2 g O |
J05AE05 |
sirolinus |
6 mg O |
3 mg O |
L04AA10 |
Cargando...
